Menu

TS Picks: March 16, 2016

Corrections give belated credit for immunotherapy; mosquitoes have been bugging us long before Zika; the bright side of irreproducibility 

Mar 16, 2016
Kerry Grens

WIKIPEDIA, CAROL A. JACOBSON AND JEROME RITZ

Selections from The Scientist’s reading list:
 

  • The New England Journal of Medicine is correcting three papers from a team led by the University of Pennsylvania’s Carl June, who is credited with pioneering a cancer immunotherapy. As MIT Technology Review reported this week (March 14), the publications did not appropriately credit the scientists who designed the chimeric antigen receptor critical for the treatment. “It’s been beneficial for immunotherapy,” Dario Campana, one of the now-acknowledged scientists, told Tech Review. “But we developed this receptor. There is no question about that.”  
     
  • As the Zika virus advances through the Americas, The Washington Post this week (March 14) offered a grim reminder that the pathogen is just the latest malady humans have suffered at the hands—er, bites—of mosquitoes. For a century we have known that the insects can carry deadly diseases, but efforts to destroy their populations have failed, and there’s evidence now that some mosquitoes have become resistant to a pesticide. “We thought we had taken care of the Aedes mosquito,” entomologist Janet McAllister of the US Centers for Disease Control and Prevention told the Washington Post. “Now, the problem has come back to haunt us.”
     
  • Psychology has gone through a shake-up recently after studies suggested considerable, albeit debated, reproducibility problems. Yet an article in Vox this week (March 14) looked on the bright side: “If psychology finds it has to start from scratch evaluating its hypotheses, at least it will be able to do so in a manner that’s more methodologically sound.” Quartz had a similar take: “The idea that papers are publishing false results might sound alarming but the recent crisis doesn’t mean that the entire scientific method is totally wrong. In fact, science’s focus on its own errors is a sign that researchers are on exactly the right path.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.